Zymeworks Inc. (ZYME)

NYSE: ZYME · Delayed Price · USD
5.17
-0.71 (-12.07%)
At close: May 18, 2022 4:00 PM
5.16
-0.01 (-0.19%)
Pre-market:May 19, 2022 7:04 AM EDT
Market Cap298.68M
Revenue (ttm)27.95M
Net Income (ttm)-239.88M
Shares Out57.77M
EPS (ttm)-4.61
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,400,942
Open5.75
Previous Close5.88
Day's Range5.10 - 5.85
52-Week Range4.56 - 39.41
Beta1.08
AnalystsBuy
Price Target26.61 (+414.7%)
Earnings DateMay 4, 2022

About ZYME

Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, breast, and colorectal cancer; and ZW49, a biparatopic anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or me...

IndustryBiotechnology
IPO DateApr 28, 2017
CEOAli Tehrani
Employees455
Stock ExchangeNYSE
Ticker SymbolZYME
Full Company Profile

Financial Performance

In 2021, Zymeworks's revenue was $26.68 million, a decrease of -31.50% compared to the previous year's $38.95 million. Losses were -$211.84 million, 17.3% more than in 2020.

Financial Statements

Analyst Forecast

According to 18 analysts, the average rating for ZYME stock is "Buy." The 12-month stock price forecast is 26.61, which is an increase of 414.70% from the latest price.

Price Target
$26.61
(414.70% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Zymeworks Inc. (ZYME) Reports Q1 Loss, Lags Revenue Estimates

Zymeworks Inc. (ZYME) delivered earnings and revenue surprises of -22.68% and 49.07%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

2 weeks ago - Zacks Investment Research

Zymeworks Provides Corporate Update and Reports First Quarter 2022 Financial Results

VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today reported financial results for the...

2 weeks ago - Business Wire

ALL BLUE CAPITAL ANNOUNCES LEADERSHIP TO SUPPORT PROPOSED ACQUISITION OF ZYMEWORKS, INC.

Alan Barge, MD, Oncology and Biopharmaceutical Drug Development Expert, Former Head of Oncology at AstraZeneca, Recently Joined All Blue as Oncology Drug Development Advisor Barge's Expertise and Focuse...

2 weeks ago - PRNewsWire

Short Squeeze Stocks: HCDI, ZYME and 3 Others Experts Think Are Ready to Pop

Short squeeze stocks are once again in focus this week as Fintel released its weekly Short Squeeze Leaderboard report. Let's take a look.

Other symbols:ATERHCDILIXTVERU
2 weeks ago - InvestorPlace

5 Short Squeeze Candidates To Watch This Week: Aterian, Harbor Custom Development Remain At The Top, Veru Joins

Potential short squeeze plays gained steam in 2021, with new retail traders looking for the next huge move. A short squeeze can occur when a heavily shorted stock rises in value instead of falling.

Other symbols:ATERHCDILIXTVERU
2 weeks ago - Benzinga

Zymeworks Announces Participation in Upcoming Investor Conferences

VANCOUVER, British Columbia & SEATTLE--(BUSINESS WIRE)--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing next-generation multifunctional biotherapeutics, today announce...

2 weeks ago - Business Wire

Zymeworks Inc. (ZYME) Surges 23.2%: Is This an Indication of Further Gains?

Zymeworks Inc. (ZYME) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more streng...

2 weeks ago - Zacks Investment Research

Why Is Zymeworks (ZYME) Stock Surging 30% Today?

Zymeworks (ZYME) stock is taking off on Friday after the company revealed an unsolicited offer from private equity firm All Blue Falcons FZE. The post Why Is Zymeworks (ZYME) Stock Surging 30% Today?

2 weeks ago - InvestorPlace

Why Zymeworks Stock Is Rocketing Higher on Friday

New cancer trial results from the clinical-stage biopharmaceutical company inspired a juicy buyout offer.

2 weeks ago - The Motley Fool

Zymeworks Confirms Receipt of Unsolicited, Non-Binding Proposal from All Blue Falcons

VANCOUVER, British Columbia & SEATTLE--(BUSINESS WIRE)---- $ZYME--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing next-generation multifunctional biotherapeutics, toda...

2 weeks ago - Business Wire

Zymeworks Reports Last Patient Enrolled in Pivotal Study of Zanidatamab in Treatment of HER2-Expressing Late-Line Bil...

VANCOUVER, British Columbia & SEATTLE--(BUSINESS WIRE)--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing next-generation multifunctional biotherapeutics, today announce...

2 weeks ago - Business Wire

Zymeworks Inc. (ZYME) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Zymeworks Inc. (ZYME) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

3 weeks ago - Zacks Investment Research

Zymeworks Announces Presentations at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

VANCOUVER, British Columbia & SEATTLE--(BUSINESS WIRE)--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced, in conjunctio...

3 weeks ago - Business Wire

Zymeworks to Host First Quarter 2022 Results Conference Call

VANCOUVER, British Columbia & SEATTLE--(BUSINESS WIRE)--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that managemen...

4 weeks ago - Business Wire

Zymeworks Inc. (ZYME) Reports Q4 Loss, Tops Revenue Estimates

Zymeworks Inc. (ZYME) delivered earnings and revenue surprises of 10.38% and 56.63%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Zymeworks Provides Corporate Update and Reports Year-End 2021 Financial Results

VANCOUVER, British Columbia & SEATTLE--(BUSINESS WIRE)--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing next-generation multifunctional biotherapeutics, today reported...

2 months ago - Business Wire

Earnings Preview: Zymeworks Inc. (ZYME) Q4 Earnings Expected to Decline

Zymeworks Inc. (ZYME) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

3 months ago - Zacks Investment Research

Zymeworks to Host Fourth Quarter and Full Year 2021 Results Conference Call

VANCOUVER, British Columbia & SEATTLE--(BUSINESS WIRE)--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that managemen...

3 months ago - Business Wire

Zymeworks Inc. (ZYME) Soars 5.3%: Is Further Upside Left in the Stock?

Zymeworks Inc. (ZYME) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more streng...

3 months ago - Zacks Investment Research

Zymeworks Announces Closing of Public Offering and Exercise in Full of the Underwriters' Option to Purchase Additiona...

VANCOUVER, British Columbia & SEATTLE--(BUSINESS WIRE)--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced the closing of...

3 months ago - Business Wire

Down 48.4% in 4 Weeks, Here's Why Zymeworks Inc. (ZYME) Looks Ripe for a Turnaround

Zymeworks Inc. (ZYME) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estima...

3 months ago - Zacks Investment Research

Bank on Rising P/E Investing With These 5 Top-Ranked Stocks

Want to try a different approach? Tap five stocks with increasing P/E ratios such as MEDIFAST (MED), JAKKS Pacific (JAKK), Asbury Automotive Group (ABG), Zymeworks (ZYME) and Polaris (PII).

Other symbols:ABGJAKKMEDPII
3 months ago - Zacks Investment Research

Zymeworks aims to raise $100M in public offering amid leadership shakeup

Zymeworks is looking to raise $100 million in a public offering, barely a week since new CEO Kenneth Galbraith took the reins of the biotech company, which has operations in Seattle and Vancouver, B.

3 months ago - GeekWire

Zymeworks Raises $100M Via Equity Issued At 14% Discount

The shares are offered at $8.00 per common share and the pre-funded warrants at $7.9999 per pre-funded warrant.

3 months ago - Benzinga

Zymeworks Announces Pricing of $100.0 Million Public Offering

VANCOUVER, British Columbia & SEATTLE--(BUSINESS WIRE)--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced the pricing of...

3 months ago - Business Wire